Sol-Gel Technologies (SLGL) Asset Utilization Ratio (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Asset Utilization Ratio of 0.42 for Q1 2026, up 8.49% year-over-year from 0.38 in Q1 2025, and down 30.55% quarter-over-quarter from 0.6 in Q4 2025.
Sol-Gel Technologies (SLGL) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Asset Utilization Ratio for 9 consecutive years, with 0.42 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 8.49% year-over-year to 0.42; the TTM figure through Mar 2026 stood at 0.42 (up 8.49% YoY), while the FY2025 annual figure was 0.59, up 107.31% from the prior year.
- Asset Utilization Ratio declined to 0.42 in Q1 2026 per SLGL's latest filing, from 0.6 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 61.36 in Q4 2022 and bottomed at 0.02 in Q3 2023.
- Historically, Asset Utilization Ratio has averaged 14.97 across 5 years, with a median of 0.42 in 2026.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio jumped 56136.96% — and 2023, when it slumped 99.96%.
- Sol-Gel Technologies' Asset Utilization Ratio stood at 61.36 in 2022, then plunged by 99.95% to 0.03 in 2023, then surged by 926.91% to 0.29 in 2024, then surged by 105.67% to 0.6 in 2025, then slumped by 30.55% to 0.42 in 2026.
- Business Quant data shows SLGL's Asset Utilization Ratio at 0.42 in Q1 2026, 0.6 in Q4 2025, and 0.51 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 0.42 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.42 |
| Dec 31, 2025 | 0.60 |
| Sep 30, 2025 | 0.51 |
| Jun 30, 2025 | 0.72 |
| Mar 31, 2025 | 0.38 |
| Dec 31, 2024 | 0.29 |
| Sep 30, 2024 | 0.27 |
| Jun 30, 2024 | 0.16 |
| Dec 31, 2023 | 0.03 |
| Sep 30, 2023 | 0.02 |
| Jun 30, 2023 | 0.09 |
| Dec 31, 2022 | 61.36 |
| Sep 30, 2022 | 56.92 |
| Jun 30, 2022 | 54.50 |
| Mar 31, 2022 | 48.27 |
| Dec 31, 2021 | 0.39 |
| Sep 30, 2021 | 0.10 |
| Jun 30, 2021 | 0.12 |
| Mar 31, 2021 | 0.11 |
| Dec 31, 2020 | 0.14 |